{
  "ticker": "LLY",
  "target_date": "2025-04-18",
  "actual_date": "2025-04-17",
  "collected_at": "2025-12-08T11:39:40.336341",
  "price": {
    "open": 836.01,
    "high": 853.12,
    "low": 817.16,
    "close": 835.1781616210938,
    "volume": 10853400,
    "change_1d_pct": 14.3,
    "change_7d_pct": 15.66,
    "change_30d_pct": -7.98
  },
  "technicals": {
    "rsi_14": 52.44,
    "sma_20": 782.81,
    "sma_50": 830.72,
    "macd": -19.533,
    "macd_signal": -24.048,
    "macd_histogram": 4.515,
    "bb_upper": 880.41,
    "bb_lower": 685.21,
    "price_vs_sma20_pct": 6.69,
    "price_vs_sma50_pct": 0.54,
    "volume_ratio": 2.69
  },
  "fundamentals": {
    "market_cap": 888944459776,
    "pe_ratio": 48.585007,
    "forward_pe": 43.76081,
    "price_to_book": 37.33509,
    "price_to_sales": 14.960408,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.82,
    "pct_from_52w_low": 58.97
  },
  "macro": {
    "spy": {
      "price": 523.41,
      "change_1d_pct": 0.14,
      "change_7d_pct": -4.05
    },
    "vix": {
      "level": 29.65,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.33
    },
    "dollar_index": {
      "level": 99.38
    },
    "gold": {
      "price": 3308.7
    },
    "regime": "BEAR_HIGH_VOL"
  },
  "news": [
    {
      "headline": "The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week",
      "source": "Yahoo",
      "datetime": 1745010120,
      "summary": "UnitedHealth  shares took a nosedive Thursday after slashing its annual outlook.  The healthcare conglomerate posted quarterly earnings that fell short of Wall Street\u2019s expectations and substantially downgraded its projected results for 2025.  UnitedHealth\u2014parent of the largest U.S. health insurer\u2014c",
      "url": "https://finnhub.io/api/news?id=c246b08b629c872f71eae9b7afedd3c08c9f67aaa80272c0664841510a8b6314"
    },
    {
      "headline": "Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic\u2019s Competition Grows",
      "source": "Yahoo",
      "datetime": 1745004000,
      "summary": "The company was first out with the new generation of diabetes and weight-loss treatments known as GLP1 drugs.",
      "url": "https://finnhub.io/api/news?id=8c7bcc8131194971f9cffc7153fb3e0053fee530ce35fbf44663742cf24c3dc4"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery",
      "source": "Yahoo",
      "datetime": 1744997162,
      "summary": "Eli Lilly (NYSE:LLY) experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to enhance therapeutic antibody development, while positive results from their Phase 3 trial for Orfor",
      "url": "https://finnhub.io/api/news?id=edf6f8ef766a6fe7e4040df61629de37bd69dc14c7f31af201145aa28128e0a9"
    },
    {
      "headline": "Eli Lilly promises to make new weight-loss pill in the U.S.",
      "source": "Yahoo",
      "datetime": 1744996440,
      "summary": "Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump\u2019s sweeping tariffs and his push to get companies to move production inside the country\u2019s borders.",
      "url": "https://finnhub.io/api/news?id=d98848eecc48ea45dbfc189c61dfa20fde1aea5c150ff24746500808e7240388"
    },
    {
      "headline": "H.C. Wainwright still expects Viking to \u2018differentiate\u2019 after Lilly data",
      "source": "Yahoo",
      "datetime": 1744991711,
      "summary": "H.C. Wainwright says the bar is set for oral GLP-1s following this morning\u2019s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to \u201cdifferentiate\u201d with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 da",
      "url": "https://finnhub.io/api/news?id=8def3f47e8b7d13f3f7109b0b4a553dd1b31747d399f7bee7eb9812c0d08565a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}